NCT04539795View on ClinicalTrials.gov

COVID-19 Study of Safety and Tolerability of Alvelestat

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

January 25, 2021

Primary Completion Date

October 29, 2021

Study Completion Date

October 29, 2021

Conditions

Covid19

Interventions

DRUG

Alvelestat

oral tablet

DRUG

Placebo

oral tablet

Trial Locations (1)

35294

UAB Lung Health Center, Birmingham

Sponsors

Collaborators (1)

Mereo BioPharma

All Listed Sponsors

collaborator

Mereo BioPharma

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT04539795 - COVID-19 Study of Safety and Tolerability of Alvelestat | Biotech Hunter | Biotech Hunter